Literature DB >> 22005913

Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma.

Hanadi Dib1, Mathieu C Tamby, Guillaume Bussone, Alexis Regent, Alice Berezné, Claudine Lafine, Cédric Broussard, Gérald Simonneau, Loïc Guillevin, Véronique Witko-Sarsat, Marc Humbert, Luc Mouthon.   

Abstract

Anti-endothelial cell antibodies (AECAs) have been identified in patients with systemic sclerosis (SSc) with and without pulmonary arterial hypertension (PAH) and in patients with idiopathic pulmonary arterial hypertension (iPAH). However, their target antigens remain poorly identified. Sera from 24 patients with SSc without PAH, 20 patients with SSc with PAH, 30 with iPAH and 12 healthy controls were collected. Target antigens were identified by two-dimensional electrophoresis and immunoblotting in protein extracts of human umbilical vein endothelial cells. Targeted antigens were identified by mass spectrometry. Serum immunoglobulin G from patients with SSc with or without PAH and patients with iPAH specifically recognised 110, 82 and 37 protein spots, respectively. Among others, target antigens of AECAs included lamin A/C, tubulin β-chain and vinculin. One-dimension immunoblotting experiments confirmed the identification of lamin A/C and tubulin β-chain. In conclusion, our results confirm the presence of AECA in patients with systemic sclerosis with and without pulmonary arterial hypertension and in those with idiopathic pulmonary arterial hypertension, and provide evidence for the identification of target antigens of these autoantibodies including lamin A/C and tubulin β-chain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005913     DOI: 10.1183/09031936.00181410

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  37 in total

Review 1.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

2.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 3.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Novel approaches to pulmonary arterial hypertension drug discovery.

Authors:  Yon K Sung; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Expert Opin Drug Discov       Date:  2016-02-27       Impact factor: 6.098

5.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 6.  Molecular pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 7.  Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis.

Authors:  Aaliya Yaqub; Lorinda Chung
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

Review 8.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 9.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01

10.  How does inflammation contribute to pulmonary hypertension?

Authors:  Rahul Kumar; Brian Graham
Journal:  Eur Respir J       Date:  2018-01-25       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.